 "Sun Pharma in pink post Q1 earnings")
Sun Pharmaceutical Industries has rallied 7% to Rs 543 in early morning deals on BSE after reporting a net loss of Rs 1,276 crore for the quarter ended June 30, 2013 (Q1), mainly because of the settlement of a patent infringement suit with US-based Pfizer. The drug maker had reported a net profit of Rs 795 crore in the year-ago quarter.
The company’s income from operation for the quarter grew by 31% to Rs 3,502 crore from Rs 2,683 crore in the first quarter of last year, Sun Pharma said in a statement.
Sun Pharma said it had to provide Rs 2,517 crore during the quarter to settle a patent infringement suit for Pfizer's anti-ulcer drug pantoprazole. The company said its India business generated sales worth Rs 849 crore, a 44% jump over the year-ago quarter.
The company’s EBITDA stood at Rs 1,531 crore grew by 26% YoY while EBITDA margins were at 44%, compared to 46% in Q1 last year, it added.
The US market, which contributes over half of the company's sales, contributed $364 million (Rs 2,184 crore). However, sales at Sun Pharma's Israeli subsidiary, Taro, fell 4% to $153 million, the company said.
The stock opened at Rs 521 and touched high of Rs 551 on BSE. A combined around one million shares changed hands on the counter on BSE and NSE.
The company’s income from operation for the quarter grew by 31% to Rs 3,502 crore from Rs 2,683 crore in the first quarter of last year, Sun Pharma said in a statement.
Sun Pharma said it had to provide Rs 2,517 crore during the quarter to settle a patent infringement suit for Pfizer's anti-ulcer drug pantoprazole. The company said its India business generated sales worth Rs 849 crore, a 44% jump over the year-ago quarter.
The company’s EBITDA stood at Rs 1,531 crore grew by 26% YoY while EBITDA margins were at 44%, compared to 46% in Q1 last year, it added.
The US market, which contributes over half of the company's sales, contributed $364 million (Rs 2,184 crore). However, sales at Sun Pharma's Israeli subsidiary, Taro, fell 4% to $153 million, the company said.
The stock opened at Rs 521 and touched high of Rs 551 on BSE. A combined around one million shares changed hands on the counter on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%